Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis
Takuya Koie(Hirosaki University), Yuki Tobisawa(Hirosaki University), Norihiko Tsuchiya(Yamagata University), Yasuhiro Kaiho(Tohoku University), Shintaro Narita(Akita University), Koji Mitsuzuka(Pacific Northwest Diabetes Research Institute), Takahiro Yoneyama(National Institute of Technology and Evaluation), Chikara Οhyama(Hirosaki University), Tohru Yoneyama(Hirosaki University), Yoichi Arai(Japan Atomic Energy Agency), Tomonori Habuchi(Akita University), Tatsuo Tochigi(Miyagi Prefectural Hospital Organization), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization)
Cited by 23
Related Papers
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Diversification of transcriptional modulation: Large-scale identification and characterization of putative alternative promoters of human genes
|Genome Research|2005|506